Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials. However, its specific...

Source: Diabetology and Metabolic Syndrome - April 29, 2023 Category: Endocrinology Authors: Tao Jin, Xiangrui Fu, Ming Liu and Fengshuang An Tags: Research Source Type: research